Shortages: Ozempic

You’ve probably seen the name of this drug, manufactured by Novo Nordisk, in the news lately. Ozempic is one in a class of drugs, including Wegovy (Novo Nordisk) and Mounjaro (Lilly), used to lower cardiovascular risk in patients with diabetes. Semaglutide (the active pharmaceutical ingredient in Ozempic) has also proven effective in helping patients with obesity lose weight and, as a result, demand for these drugs has made them nearly impossible to obtain through traditional pharmacies.

In March 2022, the shortage of these drugs became so acute that FDA listed semaglutide as “currently in shortage” on the agency’s Drug Shortage List. The drug has remained on that list ever since. That official action means that when a physician or other prescriber believes the drug is the right therapy for a patient, they can prescribe a compounded version of the FDA-approved drug.

More like this...

Image

Hear their stories. Protect their own words. Protect their access to compounded medicines.

On this page, we can only touch on the data that demonstrates the importance of compounded medicines to the lives of millions of people in this country. While the decision to take this vital therapy from patients and physicians might be profitable for big pharmaceutical companies, it will be disastrous for the millions of patients that those same pharmaceutical companies cannot serve!

We encourage the appropriate committees in both the House and Senate to hold hearings on this critical issue.

Explore our interactive map that demonstrates the importance of compounded medicines to patients all across the country. Filter these first-hand accounts by state to see just how vital compounded medicines are.

No. of testimonials